RCS - Aptamer Group PLC - Aptamer Group to officially open new facilities

AptamerAnnouncement

25/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221125:nRSY5652Ha&default-theme=true

RNS Number : 5652H  Aptamer Group PLC  25 November 2022

25 November 2022

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

 

Aptamer Group to officially open new state-of-the-art facilities

-       The new site will support the increased demand for Optimer
technology

-       Baroness Susan Greenfield will open the new site

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
enable innovation in the life sciences industry, announces that it will today
officially open its new facilities in York Science Park, UK, that will allow
it to meet the increasing demand for Optimer technology.

Aptamer's new facilities have tripled the Group's previous footprint and
include new containment level 1 and 2 laboratories. This state-of-the-art site
will help to expand the capacity of Aptamer's proprietary Optimer platform to
deliver novel binders for scientists across the bioprocessing, diagnostic, and
drug development sectors. In addition to Optimer discovery and development, a
portion of the new lab space will be dedicated to validation and assay
development to provide turnkey solutions for its customers and partners.

Optimer binders are next-generation aptamers that can be used as synthetic
antibody alternatives. They offer key benefits of smaller size, reduced
immunogenicity, increased stability, and ethical compliance as their
discovery, development, and manufacture are animal-free. These binders are
enabling researchers to pursue new targets and applications, such as targeted
drug delivery, that have previously proven intractable with protein-based
technologies.

The eminent neuroscience researcher Baroness Susan Greenfield will open the
new 18,000 sq ft site today with York Central's MP Rachel Maskell. The
visitors will receive a tour of the new premises with a presentation from
Baroness Greenfield regarding scientific discovery within growing biotech
companies. No new information will be disclosed at the opening of the new
site.

"We are excited to move to the new purpose-developed site for Aptamer Group,
which will enable us to keep up with the increased demand for our Optimer
technology at our new larger lab and office facilities," commented Dr Arron
Tolley, Chief Executive Officer of Aptamer Group.

Baroness Susan Greenfield, visiting Aptamer's new site today, said: "I'm
delighted to support a British company, clearly flourishing with an exciting
new technology!"

 

Dr Arron Tolley continued: "This expansion will mean Aptamer is able to work
on larger-scale projects that can be processed faster to support our partners
with Optimers as a robust and much-needed alternative to antibodies."

- ENDS -

 

For further information, please contact:

Aptamer Group plc

Dr Arron Tolley
 
                        +44 (0) 1904 217 404

 

Consilium Strategic Communications

 

Matthew Neal / Chris Welsh / Lucy Featherstone
 
+44 (0) 20 3709 5700

 
aptamergroup@consilium-comms.com (mailto:aptamergroup@consilium-comms.com)

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/) Group develops custom affinity binders
through its proprietary Optimer(®) platform to enable new approaches in
therapeutics, diagnostics and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through its proprietary Optimer(®) platform.

Optimer(®) binders are oligonucleotide affinity ligands that can serve as
antibody alternatives in a variety of applications across different life
science sectors. The global antibody market is currently worth over $145.0
billion. Optimer(®) binders are engineered to address many of the issues
found with alternative affinity molecules, such as antibodies, and offer new,
innovative solutions to bioprocessing, diagnostic and pharmaceutical
scientists.

Aptamer Group has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the Optimer(®) technology and processes, scientists and
collaborators can make faster, more informed decisions to support discovery
and development across the Life Sciences.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFETLILSFIF